Phathom Pharmaceuticals (PHAT) Enterprise Value (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Enterprise Value of -$185.3 million for Q2 2026, down 21.59% year-over-year from -$236.4 million in Q2 2025, and down 0.86% quarter-over-quarter from -$183.8 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Enterprise Value (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Enterprise Value for 9 consecutive years, with -$185.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 21.59% year-over-year to -$185.3 million; the TTM figure through Jun 2026 stood at -$185.3 million (down 21.59% YoY), while the FY2025 annual figure was -$132.8 million, up 55.74% from the prior year.
- Enterprise Value eased to -$185.3 million in Q2 2026 per PHAT's latest filing, from -$183.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$130.1 million in Q1 2023 and bottomed at -$384.3 million in Q4 2023.
- Historically, Enterprise Value has averaged -$218.3 million across 5 years, with a median of -$202.6 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 149.92% — and 2025, when it soared 59.11%.
- Phathom Pharmaceuticals' Enterprise Value stood at -$155.9 million in 2022, then slumped by 146.49% to -$384.3 million in 2023, then grew by 21.89% to -$300.1 million in 2024, then soared by 55.74% to -$132.8 million in 2025, then slumped by 39.53% to -$185.3 million in 2026.
- Business Quant data shows PHAT's Enterprise Value at -$185.3 million in Q2 2026, -$183.8 million in Q1 2026, and -$132.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -185.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -185.34 Mn |
| Mar 31, 2026 | -183.77 Mn |
| Dec 31, 2025 | -132.83 Mn |
| Sep 30, 2025 | -138.02 Mn |
| Jun 30, 2025 | -149.57 Mn |
| Mar 31, 2025 | -215.18 Mn |
| Dec 31, 2024 | -300.13 Mn |
| Sep 30, 2024 | -337.54 Mn |
| Jun 30, 2024 | -279.10 Mn |
| Mar 31, 2024 | -325.10 Mn |
| Dec 31, 2023 | -384.26 Mn |
| Sep 30, 2023 | -216.54 Mn |
| Jun 30, 2023 | -249.38 Mn |
| Mar 31, 2023 | -130.08 Mn |
| Dec 31, 2022 | -155.89 Mn |
| Sep 30, 2022 | -197.34 Mn |
| Jun 30, 2022 | -207.90 Mn |
| Mar 31, 2022 | -138.60 Mn |
| Dec 31, 2021 | -183.42 Mn |
| Sep 30, 2021 | -224.62 Mn |